Over the next few months Boehringer Ingelheim is anticipating temporary interruptions in the supply of certain Metacam oral presentations, along with Pexion and Semintra. The disruption in supply of these products is likely to be significant for veterinary practices in the UK.

This is due to the impact of the Covid-19 pandemic. Due to the local conditions at one of our manufacturing sites, which is located in a region of the world badly affected by Covid-19, the implementation of additional safety measures at the site has become critical. These measures have resulted in a considerable reduction in the workforce and, consequently, the output at our plant has been temporarily reduced. As a result, we anticipate that it will take a few months before we resume normal supply levels.

> We anticipate that it will take a few months before we resume normal supply levels

We sincerely apologise for this disruption but we hope you understand that this situation is beyond anyone's control. Please know that we are actively and urgently pursuing all options available to achieve a normalised supply, and Boehringer Ingelheim Animal Health in the UK is working closely with our colleagues at the manufacturing site to understand the impact of these delays so we can continue to communicate with our customers to give as clear a picture as possible.

Animal health and welfare continues to be our key focus and we understand how important these products are for the animals under your care. Information outlining the proactive steps that we are asking your practice to take to help keep as many patients as possible in supply of Metacam, and to secure supply of Pexion for patients most in need, can be accessed at [bit.ly/BIAHSupport](bit.ly/BIAHSupport). Please read this information carefully and share it with your colleagues.

If you wish to discuss a specific case please contact our technical services team, telephone 01344 746957.
